# Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.

> **NCT04625725** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 5197 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** AZD7442
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04625725
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-21
- **Primary completion:** 2022-08-16
- **Final completion:** 2023-12-08
- **Target enrollment:** 5197 (ACTUAL)
- **Last updated:** 2024-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04625725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04625725, "Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04625725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*